



Full Length Research Article

Advancements in Life Sciences – International Quarterly Journal of Biological Sciences

ARTICLE INFO

Date Received:
18/04/2020;
Date Revised:
20/08/2020;
Date Published Online:
31/08/2020;

Authors' Affiliation:
Laboratory of
Gene Technology, Institute of
biotechnology, Hue
Univeristy - VietNam

***Corresponding Author:**
Nguyen Thi Thu Lien
Email:
nttliencsh@hueuni.edu.vn

How to Cite:
Quang HT, Thi PT, Lan TT,
Huy ND, Tram NDQ, Lien
NTT (2020). Development of
a diagnostic scar marker for
Vibrio shilonii caused acute
hepatopancreatic necrosis
disease in whiteleg shrimp.
Adv. Life Sci. 7(4): 257-263.

Keywords:
AHPND; RAPD; SCAR;
Vibrio shilonii; Vietnam

Open Access



Development of a diagnostic scar marker for *Vibrio shilonii* caused acute hepatopancreatic necrosis disease in whiteleg shrimp

Hoang Tan Quang, Pham Thi Diem Thi, Tran Thuy Lan, Nguyen Duc Huy, Nguyen Duy Quynh Tram, Nguyen Thi Thu Lien*

Abstract

Background: In a previous report, we showed that *Vibrio shilonii* was found on whiteleg shrimp (*Litopenaeus vannamei*) with acute hepatopancreatic necrosis disease in Thua Thien Hue province, Vietnam. This study was performed to develop a diagnostic molecular marker generated by random amplified polymorphic DNA (RAPD) for *V. shilonii* rapid detection.

Methods: Pathogen *Vibrio* spp. were isolated from shrimps and fishes, and were identified by 16S rRNA sequencing. Genetic diversity of *Vibrio* strains was analysis by RAPD technique. Specific PCR product for *V. shilonii* was cloned and sequenced. SCAR marker was developed from specific PCR product.

Result: Twenty random primers were evaluated for RAPD to identify DNA polymorphisms between *Vibrio* species. The random primer OPN-06 generated a 468-bp DNA fragment specific for *V. shilonii*. This was then converted into a sequence-characterized amplified region (SCAR) marker designated N6-441.

Conclusion: Specific primers (Vshi-441F/Vshi-441R) amplified a unique DNA fragment in all *V. shilonii* isolates but not in the other *Vibrio* spp. This PCR assay showed significantly sensitive to the target DNA and reliably for the amplification the *V. shilonii* genome.



Introduction

Whiteleg (*Litopenaeus vannamei*) is the most popular shrimp species for commercial cultivation due to their survival advantages, fast growth rate and strong adaptability to environment [1]. The shrimp is currently cultivated in various areas in the world including Southeast Asia, China, India, United States, Mexico, and Latin America countries. Shrimp industry produced more than 4 million tons in 2016 [2]. Whiteleg and black tiger (*Penaeus monodon*) shrimps are the most common farm-based shrimp species cultured in Vietnam [3]. However, the diseases are highly occurred and directly affected to shrimp farming industry [4].

Thua Thien Hue is a province that is located in Central of Vietnam. It has a biggest lagoon in the Southeast Asia (Tam Giang lagoon) which plays significantly importance role in the aquaculture farming industry. Aquaculture has been developing in Thua Thien Hue province for 50 years ago and became the most important livelihood activity. However, aquaculture productivity decreased continuously since 2009 until now. The main reason is because of the disease outbreak, natural disasters, climate change and the environment issues, especially water pollution, impacting on the health of aquatic animals. Many farmers lost their production due to the bloom of pathogenic *Vibrio* sp. and viral shrimp diseases related to increasing water temperature [5].

In 2009, acute hepatopancreatic necrosis disease (AHPND) has caused remarkable mortality (up to 100%) in populations of shrimp cultured in South East Asia and Latin America countries. This disease is referred to as early mortality syndrome (EMS). AHPND is caused by several *Vibrio* species, which carry out the genes encode for toxic proteins similar to *Photobacterium* insect-related (Pir) toxins [6,7]. The marine bacterium *Vibrio shilonii* was firstly identified in the coastal areas of the Mediterranean Sea and has been proposed as the agent factor causing the bleaching disease for *Oculina patagonica* [8]. It was recently reported that *V. shilonii* caused the acute hepatopancreatic necrosis disease (AHPND) on shrimp in Ecuador and Vietnam [5,7].

Random amplified polymorphic DNA (RAPD) is rapid and powerful tool for generating molecular markers to differentiate organism population. However, RAPD is limited by inherent low reliability and reproducibility of the PCR reaction. Thus, a RAPD-derived codominant and reproducible marker was developed and called as the sequence-characterized amplified region (SCAR) [9]. Using SCAR markers for identification of pathogens such as *Pseudomonas syringae* [10], *Pseudofabrea citricarpa* [11], and *Bipolaris sorokiniana* [12]. However, SCAR markers to identify *Vibrio* species have not been previously reported.

In Thua Thien Hue, five strains of *V. shilonii* were found on whiteleg shrimp with AHPND [5]. However, no more information of these five strains has been published. This study aimed to develop a molecular marker for the rapid *V. shilonii* identification and to provide scientific data as the basis for the study, and to contribute to the production of rapid diagnostic kits for pathogens *Vibrio* in the future.

Methods

Vibrio strains

Vibrio strains were provided by the Laboratory of Gene Technology, Institute of Biotechnology, Hue University, Vietnam (Table 1). Characteristics of each strain were previously described [5].

DNA isolation

Vibrio colonies were cultured in alkaline saline peptone water medium with 2% peptone and 2% NaCl, pH 8.6, with shaking at 180 rpm for 18 h at 30°C. Cells were collected using centrifugation with 13,000 rpm at 4°C for 1 min. Total genomic DNA was extracted by the AquaPure Genomic DNA Isolation Kit (Cat. 732-6340, Bio-rad) according to the manufacturer's recommendations, and stored at 4°C. Total DNA concentrations were determined using a photo spectrometer at 260/280 nm. Genomic DNA was adjusted to final concentration of 50 ng/μL for PCR amplification.

RAPD analysis

Genomic DNA pools of each species were used as templates for RAPD analysis (Table 1). DNA pool samples were prepared by mixing genomic DNA of all strains from each species into one unique sample with an equal ratio. A total of 20 RAPD primers (Operon Technologies, USA) were assayed for detecting *Vibrio shilonii* species (Table 2), these primers were used in our previous study [5] of randomly selected. Specific bands (absent in the other *Vibrio* species) were replicated twice for confirmation used for further studies. PCR-RAPD reactions were carried out according to Quang *et al.* [5].

DNA pool codes	Species	No. of strains	Sample codes
N1	<i>Vibrio parahaemolyticus</i>	13	VT19, VT34, VT41, VT44, VT59, VT62, VX01, K5, VT56, VC85, VC59, VC39, VC41
N2	<i>Vibrio shilonii</i>	5	VT23, VT26, VT27, VT29, VT33
N3	<i>Vibrio vulnificus</i>	6	VC15, VC17, VC21, VC28, VC37, VC67
N4	<i>Vibrio harveyi</i>	3	VC24, VC25, VC45
N5	<i>Vibrio cholera</i>	3	VC43, VC53, VC61
N6	<i>Vibrio communis</i>	1	VT47
N7	<i>Vibrio furnissii</i>	1	VT65
N8	<i>Vibrio brasiliensis</i>	1	VC52

Table 1: DNA pool of *Vibrio* samples [5].

DNA fragment cloning and sequencing

The specific amplicon of *V. shilonii* was extracted, then purified with GeneJET Gel Extraction Kit (Thermo Scientific, Lithuania). The purified PCR product was cloned into pGEM-T Easy vector (Promega, USA) and transferred into *Escherichia coli* strain TOP10 competent cells heat shock method [13]. Positive clones were confirmed by PCR with M13 primers and sequenced at Firstbase company (Malaysia).

SCAR marker development

Specific SCAR primers Vshi-441F and Vshi-441R were designed based on the sequenced RAPD amplicon (Table 3). Genomic DNA samples, including those from five *V. shilonii* strains and other pathogen *Vibrio* species, were amplified using the Vshi-441F and Vshi-441R primers to verify the SCAR marker specificity. A 12 µL PCR reaction system was developed containing 50 ng of total DNA, 10 pmol of each primer, 6 µL 2x GoTaq® Green Master Mix (Promega, USA), and sterile distilled water. PCR amplification was performed as follows: 95°C for 5 min; 35 cycles at 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min; the final cycle at 72°C for 10 min.

To test detection sensitivity, 0.01–10 ng/µL of diluted genomic DNA of *V. shilonii* were evaluated as DNA templates for PCR amplification.

Primer Code	Nucleotide sequence (5'-3')	Number of amplified bands for <i>V. shilonii</i>	Number of specific bands	Name of specific band
OPA-01	CAGGCCCTTC	1	0	-
OPA-02	TGCCGAGCTG	3	1	A02-350
OPA-03	AGTCAGCCAC	3	0	-
OPA-09	GGGTAACGCC	5	1	A09-2000
OPA-11	CAATCGCCGT	2	2	A11-850 and A11-500
OPB-01	GTTTCGCTCC	2	1	B01-1200
OPB-04	GGACTGGAGT	5	1	B04-1600
OPB-18	CCACAGCAGT	2	1	B18-250
OPC-13	AAGCCTCGTC	0	0	-
OPD-02	GGACCAACC	6	1	D02-1200
OPD-07	TTGGCACGGG	1	0	-
OPD-11	AGCGCCATTG	3	1	D11-1400
OPF-04	GGTGATCAGG	4	0	-
OPF-08	GGGATATCGG	0	0	-
OPG-06	GTGCCTAACC	0	0	-
OPG-10	AGGGCCGTCT	1	1	G10-750
OPG-17	ACGACCGACA	3	0	-
OPK-13	GGTTGTACCC	2	0	-
OPN-03	GGTACTCCCC	2	1	N03-900
OPN-06	GAGACGCACA	1	1	N06-450
Total		46	12	

Table 2: RAPD primer selection for *Vibrio shilonii*.

Results

RAPD analysis

To reduce the number of test samples, we used a DNA pool instead of individual genomic DNA for specific RAPD amplicons. The DNA pool in this study was a mixture of genomic DNA of strains of each *Vibrio* species at an equal ratio: eight DNA pool samples for *V. parahaemolyticus*, *V. vulnificus*, *V. shilonii*, *V. cholera*, *V. communis*, *V. harveyi*, *V. furnissii*, and *V. brasiliensis* (Table 1).

From 20 tested random primers, we obtained 46 DNA fragments from *Vibrio shilonii* (0–6 DNA bands/primer); most of these were polymorphic bands (Figure 1). Twelve specific bands for *V. shilonii* were generated from 11 primers (Table 2), and these primers were used for




Figure 1. Representative specific DNA bands from PCR-RAPD with a DNA pool template. M. DNA molecular size marker (GeneRuler™ DNA 1 kb ladder, Thermo Fisher Scientific). White arrows indicate specific bands. (A) OPA-11 and OPB-01 primers. (B) OPB-04 and OPB-18 primers. (C) OPN-06 and OPD-02 primers.




Figure 2: RAPD profile of *Vibrio* spp. with selected primer. M. DNA molecular size marker (GeneRuler™ DNA 1 kb ladder, Thermo Fisher Scientific). White arrows indicate the specific bands. (A) Primer OPA-11. (B) Primer OB-18. (C) Primer OPN-06.

```

N06_468          GAGACGCACATAAGGTAAGTGCAGATTGTTACGCGGAAAATGTCGGTTCTTACAAAAC
CP009355       TTAAGGCGCATAAAGTCAGTGCAGATTGCTACTCATCGAATGTGGGTTCATACAAAACGT
CP025797       TAAACGCCCATAAAGTCAGTGCAGATTGCTACGCTTCTAATGTGGTCTTACAAGACGT
CP025793       TAAACGCCCATAAAGTCAGTGCAGATTGCTACGCTTCTAATGTGGTCTTACAAGACGT
CP013485       TAAACGCCCATAAAGTCAGTGCAGATTGCTACGCTTCTAATGTGGTCTTACAAAAACGT
                * ** ***** * ***** ***** * ** *   *** * * ***** **

N06_468          TTGAGAAGTGTGGCTTCGTTCAAGGAAGGACGTCAGAAAGACTACTATAAGCTTGGACAGC
CP009355       TAGAGAAATGCGGCTTTAGCCAAGAAGGACGTCAGACAGACTATTACAAGCTAGAGGAAG
CP025797       TAGAGAAAAATGGTTTTACTCAAGAAGGCCGTCAGAAAGACTACTACAACTAGAGCAAG
CP025793       TAGAGAAAAATGGTTTTACTCAGGAAGGCCCTTCAAGAAAGACTACTATAAACGAGAGCAAG
CP013485       TAGAGAAAAATGGTTTTACTCAAGAAGGCCGTCAGAAAGACTACTACAAACGAGAGCAAG
                * ***** * * * * *   ** ***** * ***** ***** * * * * * * * * *

N06_468          GTTTTGATGACGAGCTCTATTATGGCATGACAGCCGAGCAGTTCAAGTGCATTAACCCGCT
CP009355       GCTTGGAAGACAAGCTTTACTACGGTATGACAGCAGACAATTTCGCTCTTTCAATCGTT
CP025797       GCTTTGACGACAAGCTTTACTACGGTATGACCGCAGACAATTTCGCTCTTTAAATCGCT
CP025793       GCTTTGACGATAAACTTTACTACGGTATGACCGCAGACAATTTCGCTCTTTAAATCGCT
CP013485       GCTTTGACGACAAGCTTTACTACGGCATGACCGCAGACAATTTCGCTCTTTAAATCGCT
                * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

N06_468          -----GATAAAGC-----GATAAAGC-----GATAAAGC-----AAAAGCCGTTAAA
CP009355       TAG-----TGATCAAGCGACGCGTTTAAACAGC-----AAACGAAAAGGCCGCTAA--
CP025797       AATAATTAGCTGACAAAAAAGTAGCTAACAAACAGTAGCCAACAAAAAGGCCGTTAA--
CP025793       GATTATTAGCCGACAAAAAAGTAGCTAAAAACAAGTAGTGAAACAAAAAGGCCGTTAA--
CP013485       AATAATTAGCTAACAAA-----GATAAAGC-----GATAAAGC-----AAAAGCCGTTAA-
                * **                                             ***** **

N06_468          CACCTTAGTCGGATTAACGGCCTTTT-TGTATCAAGTG-----CTTAGTT
CP009355       TGCCCAAGATCGGGTTAGCGGCCTTTTCTATATTAATAGACC-----CTAGGTCTTAGTT
CP025797       CCCACATGCTCGGGTTAACGGCCTTTTCTATATTACGCGCTAAATGGCTAAGACTTAGTT
CP025793       CCCACATGCTCGGGTTAACGGCCTTTTCTATATTACGCGCTAAATGGCTAAGACTTAGTT
CP013485       CCCAAATGCTCGGGTTAACGGCCTTTTCTATATTACGCGCTAAATGGCAAAGGCTTAGTT
                * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

N06_468          AGCCTGGCTCTGGCTCTGAAGCTTCTCTTTGCTTCTTCAACTTTTGAGAAGTCCAATCC
CP009355       GCCTTGATTTTGGCTTTGAAGCTTCTCTTTGCTTCTTCAACTTTTGAGAAATCTAAACC
CP025797       GCCTTGATTTTGGCTTTGAAGCTTCTCTTTGCTTCTTCAACTTTTGAGAAATCCAATCC
CP025793       GCCTTGATTTTGGCTTTGAAGCTTCTCTTTGCTTCTTCAACTTTTGAGAAATCCAATCC
CP013485       GCCTTGATTTTGGCTTTGAAGCTTCTCTTTGCTTCTTCAACTTTTGAGAAATCCAATCC
                * ** * ***** ***** ***** ***** ***** * * * * *

N06_468          CAACTCTTCAACCGCTCTTTGATTAGCGCAGGGTTTTGCATGACTTGCGCCATCAGCAT
CP009355       CAACTCATCGACGGCTCTTTGATTAGCGCAGGGTTTTGCATCACTTGCGCCATCAGCAT
CP025797       CAACTCGTCTACGGCTCTTTGATTAGCGCAGGGTTTTGCATCACTTGCGCCATCAGCAT
CP025793       CAACTCATCTACGGCTCTTTGATTAGCGCAGGGTTTTGCATCACTTGCGCCATCAGCAT
CP013485       CAATTCTGTCTACCGCTCTTTGATTAGCGCAGGGTTTTGCATCACTTGCGCCATCAGCAT
                *** ** * * * ***** ***** ***** ***** ***** *****

N06_468          TTGAAGTTGTCTTGTAGGTAAGCCCAATTGACTGATAGTTGCCATTGCAGAAAAGGGTT
CP009355       TTGTAGCTTGTCTTGTGGCAGACCTAGTTGGCTGATCGTTGCCATCGCTCAAGAGGGTT
CP025797       TTGTAGCTTGTCTTGTGGTAAACCTAGTTGGCTGATTGTGCCATTGCCGCTAGAGGGTT
CP025793       TTGTAGCTTGTCTTGTGGCAAACCTAGTTGGCTGATTGTGCCATTGCCGCTAGAGGGTT
CP013485       TTGTAGCTTGTCTTGTGGCAAGCCTAGTTGGCTGATTGTGCCATTGCCGCTAGAGGGTT
                *** ** ***** * * * * * * * * * * * * * * * * * * * *

N06_468          TTGTGTCAGAGTCTGAAAAATTCGTTGATTGTGCGTCTC
CP009355       TTGCGTCAGAGTTTGAAGATTTCGTTGATCTGTTTCATCGC
CP025797       TTGCGTCAGAGTCTGAAAAATCTCGTTGATTGTGCTCATCGC
CP025793       TTGCGTCAGAGTCTGAAAAATCTCGTTGATTGTGCTCATCGC
CP013485       TTGCGTCAGAGTCTGAAAAATCTCGTTGATTGTGCTCATCGC
                *** ***** * * * * * * * * * * * * * * *
    
```

Figure 3: Multi-alignment of N06-450 marker with other *Vibrio* sequences. CP009355, *V. tubiashii* ATCC 19109; CP025797, *V. owensii* 051011B; CP025793, *V. jasicida* 090810c; CP013485, *V. alginolyticus* ATCC 33787. Underlined sequences indicate SCAR primers.



amplification of all samples. Specific PCR products generated from these 11 primers were used to screen specific markers for *V. shilonii*. Results showed that the 12 specific bands were present in five strains of *V. shilonii* and absent in other *Vibrio* species (Figure 2). Of 12 PCR products, N06-450 fragment (designated as the primer name and expected size of the band) was chosen to develop the SCAR marker because it produced a clear band of the suitable size (~450 bp) and was sufficiently different from RAPD patterns of other pathogens. However, the OPN-06 primer amplified only one PCR product, so further research was easily performed with this band.

SCAR marker development

The N06-450 band was chosen to develop the SCAR marker. Thus, the PCR band was cloned into pGEM-T Easy vector and performed DNA sequencing. The results indicated that the length of the amplicon was 468 bp with 44.4% GC content (A = 119, T = 141, G = 111, and C = 97) (Figure 3).

BLAST results showed no significant similar sequence on Genbank database. The similarity coefficient of the N06-450 sequence with other *Vibrio* species ranged from 74%–78%: *V. alginolyticus* ATCC 33787 (78.19%), *V. hyugaensis* 090810a (74.13%), *V. tubiashii* ATCC 19109 (73.52%), *V. owensii* 051011B (73.53%), or *V. jasicida* 090810c (72.75%) (Figure 3). No similar sequences were found from popular *Vibrio* pathogens such as *V. parahaemolyticus*, *V. brasiliensis*, *V. communis*, *V. furnissii*, and *V. harveyi*.

The primer pair Vshi-441F/Vshi-441R (Table 3) was designed based on the comparison of N06-450 sequences and others from Genbank (Figure 3 and Table 3). The Vshi-441F/Vshi-441R primers were selected to amplify on genomic DNA of pathogenic *Vibrio* isolates. A unique band with the size approximately of 441 bp was observed in *V. shilonii* isolates only (Figure 4), indicating that the designed SCAR marker was specific for this species, (this SCAR marker was named N6-441).

Primer name	Sequence	Product length
Vshi-441F	5'-GTTACGCGGAAAATGTCGGT-3'	441 bp
Vshi-441R	5'-GAGACGCACAAATCAACGAG-3'	

Table 3: Sequences of SCAR primers.




Figure 4: Specific SCAR marker test. M. DNA molecular size marker (GeneRuler™ DNA 1 kb ladder, Thermo Fisher Scientific). Lane 0, negative control; lane 1, *V. parahaemolyticus*; lane 2, *V. vulnificus*; lane 3-7, *V. shilonii*; lane 8, *V. cholera*; lane 9, *V. harveyi*; lane 10, *V. communis*; lane 11, *V. furnissii*; lane 12, *V. brasiliensis*.




Figure 5: Sensitivity test of SCAR primers. M. DNA molecular size marker (GeneRuler™ DNA 1 kb ladder, Thermo Fisher Scientific). lane 1: 10 ng/μL; lane 2: 5 ng/μL; lane 3: 1 ng/μL; lane 4: 0.5 ng/μL; lane 5: 0.1 ng/μL; lane 6: 0.01 ng/μL; lane 7: negative control.

To evaluate the SCAR marker sensitivity for *V. shilonii* identification, serially diluted *V. shilonii* genomic DNA were used as templates for the PCR assay using Vshi-441F/Vshi-441R primers. The results revealed that this SCAR marker detected *V. shilonii* DNA at concentration of 100 pg/μL or higher (Figure 5).

Discussion

Vibrio spp. have been traditionally identified by culture the isolate on selective blood agar medium in integration with biochemical and serological testing. These methods are simple but require a lot of time and technicians. Meanwhile, PCR method has high advantages for rapid identification of *Vibrio* spp. in laboratory targeting the defined DNA sequences on genomic DNA. Furthermore, this method is often selected to amplify the specific targeted DNA sequence of the heterogeneous collection [14].

RAPD is a PCR-based technique to amplify the target or random DNA fragment using random primers. RAPDs are simple assay with fast results. This technique does not require sequence data as well as randomly genome distribution, and nature dominant. RAPD marker disadvantage is that this method is not able to identify the organism species due to their low reproducibility and nature dominant. Thus, RAPD marker recently is being developed into a codominant and reproducible marker (SCAR), which is able for species identification [15]. Using SCAR markers for identification of animal pathogens has been reported for such pathogens as *Eimeria* species [9] and *Actinobacillus pleuropneumoniae* [16].

Molecular diagnostic methods for *Vibrio* spp. detection based on PCR have been reported including loop-mediated isothermal amplification assay for *V. parahaemolyticus* [17], multiplex PCR for *Vibrio* spp. [18], or *V. vulnificus* [19]. Conventional PCR for specific *Vibrio* spp. genes also have been reported [20]. However, to our knowledge, no SCAR marker methods for diagnosing *Vibrio* spp. have been published heretofore.

In this study, we developed a rapid and highly specific SCAR marker for *V. shilonii* identification and detection.

The method was developed based on specific primers designed for conventional PCR which is able to replace the traditional microbiology method. Our newly developed method is applicable for epidemiological studies as well as contribution to the protection programs for aquaculture.

Using the RAPD technique, we found a high diversity of *Vibrio* species except for *V. shilonii*, which is crucial for specific DNA fragments selection of the species. The designed primers for *V. shilonii* was evaluated the specificity by sequencing the amplified regions, followed by BLAST analysis because these sequences did not show significant similarities within the NCBI database (Figure 3).

The results in this study therefore show the SCAR primers can be applied to directly detect *V. shilonii* strains. The specificity of these primers was evaluated based on genomic DNA from eight *Vibrio* spp. demonstrated the positive amplification only observed on DNA of the targeted species.

The results of this study show a high level of polymorphism in the RAPD pattern of the different *Vibrio* species, and a SCAR marker (N6-441) was developed based on the 468-bp sequence specific to *V. shilonii*. Specific primers (Vshi-441F/Vshi-441R) amplified a unique DNA fragment for all *V. shilonii* isolates but not in the other *Vibrio* spp. This PCR method was highly sensitive to the *V. shilonii* genome and thus may be useful in rapid detection of this pathogenic bacterium.

Authors' Contribution

Hoang Tan Quang: experimental design, data analysis, paper preparation

Pham Thi Diem Thi: experimental performant

Tran Thuy Lan: experimental performant

Nguyen Duc Huy: paper preparation

Nguyen Duy Quynh Tram: experimental performant

Nguyen Thi Thu Lien: project leader, experimental design, paper preparation

Competing Interest

The authors declare that they have no competing interests.

Acknowledgement

This study was financial supported from Vietnam Ministry of Education and Training (Project No. CT-2018-DHH-02).

References

- Li J, Jiang H, Li L, Zhang X, Chen J. The Effect of Disease and Season to Hepatopancreas and Intestinal Mycobiota of *Litopenaeus vannamei*. *Frontiers in Microbiology*, (2019); 10:889-889.
- FAO (2020) Cultured aquatic species information programme: *Penaeus vannamei* (Boone, 1931). http://www.fao.org/fishery/culturedspecies/Penaeus_vannamei/en. Date accessed: 08/20/2020.
- Thakur K, Patanasatienkul T, Laurin E, Vanderstichel R, Corsin F, et al. Production characteristics of intensive whiteleg shrimp (*Litopenaeus vannamei*) farming in four Vietnam Provinces. *Aquaculture Research*, (2018); 49(8): 2625-2632.
- Huy ND, Ngoc LMT, Loc NH, Lan TT, Quang HT, et al. Isolation of *Weissella cibaria* from Pacific white shrimp (*Litopenaeus vannamei*) gastrointestinal tract and evaluation of its pathogenic bacterial inhibition. *Indian Journal of Science & Technology*, (2020); 13(10): 1200-1212.
- Quang HT, Lan TT, Hai TTH, Yen PTH, Van TQK, et al. Genetic diversity and toxic genes analysis of *Vibrio* spp. isolated from white leg shrimp and marine fishes cultured in Tam Giang lagoon in Thua Thien Hue province, Vietnam. *Indian Journal of Science & Technology*, (2020); 13(13): 1412-1422.
- Han JE, Tang KFJ, Piamsomboon P, Pantoja CR. Evaluation of a reliable non-invasive molecular test for the diagnosis of the causative agent of acute hepatopancreatic necrosis disease of shrimp. *Aquaculture Reports*, (2017); 5: 58-61.
- Han JE, Tang KFJ, Tran LH, Lightner DV. Photorhabdus insect-related (*Pir*) toxin-like genes in a plasmid of *Vibrio parahaemolyticus*, the causative agent of acute hepatopancreatic necrosis disease (AHPND) of shrimp. *Diseases of Aquatic Organisms*, (2015); 113(1): 33-40.
- González Y, Venegas D, Mendoza-Hernandez G, Camarena L, Dreyfus G. Na⁺- and H⁺-dependent motility in the coral pathogen *Vibrio shilonii*. *FEMS Microbiology Letters*, (2010); 312(2): 142-150.
- Fernandez S, Katsuyama A, Kashiwabara AY, Madeira A, Durham A, Gruber A. Characterization of SCAR markers of *Eimeria* spp. of domestic fowl and construction of a public relational database (The *Eimeria* SCARdb). *FEMS Microbiology Letters*, (2004); 238(1): 183-188.
- Kalužna M, Albuquerque P, Tavares F, Sobiczewski P, Puławska J. Development of SCAR markers for rapid and specific detection of *Pseudomonas syringae* pv. *morsprunorum* races 1 and 2, using conventional and real-time PCR. *Applied microbiology and biotechnology*, (2016); 100(8): 3693-3711.
- Yang Y, Hu J, Chen F, Ding D, Zhou C. Development of a SCAR marker-based diagnostic method for the detection of the *Citrus* target spot pathogen *Pseudofabrya citricarpa*. *BioMed Research International*, (2018); article ID 7128903.
- Aggarwal R, Gupta S, Banerjee S, Singh V. Development of a SCAR marker for detection of *Bipolaris sorokiniana* causing spot blotch of wheat. *Canadian journal of microbiology*, (2011); 57:934-942.
- Reid GA. *Molecular cloning: A laboratory manual*, 2nd edn. by J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbor Laboratory Press, 1989. \$115.00 (3 vols; 1659 pages) ISBN 0 87969 309 6. *Trends in Biotechnology*, (1991); 9(1): 213-214.
- Ramazanzadeh R, Rouhi S, Shakib P, Shahbazi B, Bidarpour F, et al. Molecular characterization of *Vibrio cholerae* isolated from clinical samples in Kurdistan province, Iran. *Jundishapur journal of microbiology*, (2015); 8(5): e18119-e18119.
- Sairkar PK, Sharma A, Shukla NP. SCAR marker for identification and discrimination of *Commiphora wightii* and *C. myrrha*. *Molecular Biology International*, (2016); 20161482796-1482796.
- Rossi CC, Pereira MF, Langford PR, Bazzolli DMS. A BOX-SCAR fragment for the identification of *Actinobacillus pleuropneumoniae*. *FEMS Microbiology Letters*, (2014); 352(1): 32-37.
- Anupama KP, Chakraborty A, Karunasagar I, Maiti B. Loop-mediated isothermal amplification assay as a point-of-care diagnostic tool for *Vibrio parahaemolyticus*: recent developments and improvements. *Expert Review of Molecular Diagnostics*, (2019); 19(3): 229-239.
- Kim HJ, Ryu JO, Lee SY, Kim ES, Kim HY. Multiplex PCR for detection of the *Vibrio* genus and five pathogenic *Vibrio* species with primer sets designed using comparative genomics. *BMC Microbiology*, (2015); 15(1): 239-250.
- Tsai YH, Chen PH, Yu PA, Chen CL, Kuo LT, Kuo CH. A multiplex PCR assay for detection of *Vibrio vulnificus*, *Aeromonas hydrophila*, methicillin-resistant *Staphylococcus aureus*, *Streptococcus pyogenes*, and *Streptococcus agalactiae* from the isolates of patients with necrotizing fasciitis. *International Journal of Infectious Diseases*, (2019); 81: 73-80.
- Alramahy SK. Molecular diagnostics for *Vibrio cholera* based on *recA* gene isolated from human in Diwanayah city. *Journal of Pharmaceutical Sciences and Research*, (2018); 10(5): 1125-1127.
- Hänninen J, Takala J, Keinänen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. *Diabetes Research and Clinical Practice*, (1998); 42(1): 17-27.
- Senez B, Felicioli P, Moreau A, Goaziou M-FL. Quality of life assessment of type 2 diabetic patients in general medicine. *Presse Médicale*, (2004); 33(3): 161-166.

23. Kazemi-Galougahi MH, Ghaziani HN, Ardebili HE, Mahmoudi M. Quality of life in type 2 diabetic patients and related effective factors. *Indian Journal of Medical Sciences* (2012); 66(9-10): 230-237.
24. Shaheen F, Basit A, Riaz M, Fawwad A, Hakeem R, *et al.* Assessing health related quality of life in diabetic subjects by SF 36 questionnaire in a tertiary care diabetes unit of Karachi, Pakistan. *International Journal of Advanced Research*, (2014); 6(6): 13-17.
25. Moreau A, Senez B, Felicioli P, Goaziou M-FL. Évaluation de la qualité de vie des patients diabétiques de type 2 en médecine générale. *Presse Médicale*, (2003); 17(608): 1-5.
26. Finkelstein MM. Body mass index and quality of life in a survey of primary care patients. *Journal of Family Practice*, (2000); 49(8): 734-737.
27. Eckert K. Impact of physical activity and bodyweight on health-related quality of life in people with type 2 diabetes. *Diabetes, Metabolic Syndrome and Obesity*, (2012); 5303-311.
28. Woodcock AJ, Julious SA, Kinmonth AL, Campbell MJ. Problems with the performance of the SF-36 among people with type 2 diabetes in general practice. *Quality of Life Research*, (2001); 10(8): 661-670.
29. Gulliford MC, Mahabir D. Relationship of health-related quality of life to symptom severity in diabetes mellitus: a study in Trinidad and Tobago. *Journal of Clinical Epidemiology*, (1999); 52(8): 773-780.
30. Larsson D, Lager I, Nilsson PM. Socio-economic characteristics and quality of life in diabetes mellitus--relation to metabolic control. *Scandinavian Journal of Public Health*, (1999); 27(2): 101-105.
31. Clouet F, Excler-Cavailher G, Christophe B, Masson F, Fasquel D. [Type 2 Diabetes and Short Form 36-items Health Survey]. *Diabetes & Metabolism*, (2001); 27(6): 711-717.
32. Ikeda A, Iso H, Toyoshima H, Fujino Y, Mizoue T, *et al.* Marital status and mortality among Japanese men and women: the Japan Collaborative Cohort Study. *BMC Public Health*, (2007); 773. Liu H. Till Death Do Us Part: Marital Status and U.S. Mortality Trends, 1986 – 2000. *Journal of Marriage and Family*, (2009); 71(5): 1158-1173.
33. Wee HL, Cheung YB, Li SC, Fong KY, Thumboo J. The impact of diabetes mellitus and other chronic medical conditions on health-related Quality of Life: is the whole greater than the sum of its parts? *Health Qual Life Outcomes*, (2005); 32.
34. Poljicanin T, Ajduković D, Sekerija M, Pibernik-Okanović M, Metelko Z, *et al.* Diabetes mellitus and hypertension have comparable adverse effects on health-related quality of life. *BMC Public Health*, (2010); 1012.
35. Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. *Value Health*, (2001); 4(5): 392-400.



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. To read the copy of this

license please visit: <https://creativecommons.org/licenses/by-nc/4.0/>